IMV INC (IMV)       0.7196  +0.05 (+7.97%)

0.7196  +0.05 (+7.97%)

CA44974L1031 - Common Stock - After market: 0.72 +0 (+0.06%)


Fundamental Rating

Overall IMV gets a fundamental rating of 2 out of 10. We evaluated IMV against 644 industry peers in the Biotechnology industry. IMV has a bad profitability rating. Also its financial health evaluation is rather negative. IMV is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating


The profitability ratios for IMV are negative, so there is not much use analyzing them.
IMV's Return On Assets of -105.18% is worse than the rest of the industry. The industry average Return On Assets is -40.38%. 88% of the industry peers have a better Return On Assets.

IMV's Profit Margin of -31548.15% is worse than the rest of the industry. The industry average Profit Margin is -418.32%. 96% of the industry peers have a better Profit Margin.
The Piotroski-F score of IMV is 2.00. This is a very weak score and indicates problems in health and profitability for IMV.
VS Industry

ROA (-105.18%) VS Industry: 12% outperformed.

-1,226.49
115.38

Profit Margin (-31548.15%) VS Industry: 4% outperformed.

-442,331.25
5,207.39

Valuation

Valuation Rating


IMV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMV. No positive earnings are expected for the next year.

When comparing the current price to the book value of IMV, we can conclude it is valued rather expensively. It is trading at 24.51 times its book value.
When comparing the price book ratio of IMV to the average industry price book ratio of 1.93, IMV is valued more expensive than its industry peers. 98% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Book (24.51) VS Industry: 2% outperformed.

669.86
0.07

Growth

Growth Rating


The Revenue is expected to grow by 89.29% on average over the next 5 years. This is a very strong growth
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
The Earnings Per Share is expected to grow by 1.17% on average over the next 5 years.

Measured over the past 5 years, IMV shows a small growth in Revenue. The Revenue has been growing by 3.28% on average per year.
IMV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.17%.
The Revenue for IMV has decreased by -58.07% in the past year. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -25.17% 4.68% 3% -0.31% 1.17%
Revenue3.28% -20.2% -58.07% 2087.26% 381.31% 185.05% 89.29%

Health

Health Rating


A Current Ratio of 4.19 indicates that IMV has no problem at all paying its short term obligations.
IMV has a Quick Ratio of 4.19. This indicates that IMV is financially healthy and has no problem in meeting its short term obligations.
Compared to an average industry Current Ratio of 6.69, IMV is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.55, IMV is worse placed to pay its short term obligations than its industry peers.

IMV has one of the worst Debt to Equity ratios in its industry. 100% of its industry peers require less debt for financing their operations.
IMV has an Altman-Z score of -7.51. This is a bad value and indicates that IMV is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.49, IMV is in worse financial state than most of its industry peers. 84% of its industry peers have a better Altman-Z score.
The Piotroski-F score of IMV is 2.00. This is a very weak score and indicates problems in health and profitability for IMV.
VS Industry

Debt/Equity (12.16) VS Industry: 0% outperformed.

18.24
0.00

Quick Ratio (4.19) VS Industry: 31% outperformed.

0.04
138.86

Current Ratio (4.19) VS Industry: 31% outperformed.

0.15
140.77

Altman-Z (-7.51) VS Industry: 16% outperformed.

-253.58
1,332.86

Dividend

Dividend Rating


IMV does not give a dividend.

IMV Daily chart

IMV INC0.7196

NASDAQ:IMV (8/16/2022, 7:00:02 PM)+0.05 (+7.97%)

After market: 0.72 +0 (+0.06%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 08-11 2022-08-11/bmo Earnings (Next) 11-08 2022-11-08
Ins Owners N/A Inst Owners 11.99%
Market Cap 59.20M Analysts 77.78
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 438.53 P/B 24.51
EV/EBITDA -1.35
Profitability
ROA -105.18% ROE N/A
PM -31548.15 Asset Turnover 0
Growth
EPS 1Y -25.17% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -9.09%
EPS Next Y 4.68% EPS Next 2Y 3%
EPS Next 3Y -0.31% EPS Next 5Y 1.17%
Revenue growth 1Y -58.07% Revenue growth 3Y -20.2%
Revenue growth 5Y 3.28% Revenue growth Q2Q -69.64%
Revenue Next Year 2087.26% Revenue Next 2Y 381.31%
Revenue Next 3Y 185.05% Revenue Next 5Y 89.29%
Health
Current Ratio 4.19 Quick Ratio 4.19
Altman-Z -7.51 F-Score 2
Debt/Equity 12.16
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA